Is it relevant to use an interleukin‐1‐inhibiting strategy for the treatment of patients with deficiency of interleukin‐36 receptor antagonist?. (1st May 2014) - Tauber, M.; Viguier, M.; Le Gall, C.; Smahi, A.; Bachelez, H.